Suzuki Shuji, Kaji Satoshi, Koike Nobusada, Harada Nobuhiko, Suzuki Mamoru, Hayashi Tsuneo
Hepatogastroenterology. 2014 Mar-Apr;61(130):314-8.
BACKGROUND/AIMS: This retrospective study aimed to evaluate adjuvant chemotherapy using gemcitabine for resected distal bile duct and ampullary cancers.
Thirty-seven patients who had curative surgery for distal bile duct and ampullary cancers were classified into two groups: A, 19, surgery alone, and B, 18, surgery plus gemcitabine adjuvant chemotherapy between 2004 and 2010. Outcomes, including backgrounds, overall survival (OS), disease free survival (DFS), and adverse events are reported.
There were no differences in characteristics between patients of groups A and B for age, gender, location of tumor, UICC stage, UICC pT factor, UICC pN factor, curability, and operative procedures. For all stages, except stage II, there was no difference between groups A and B for OS and DFS. For stage II however, groups A and B showed significant differences in median survival times for OS and DFS. Grade 3 or 4 adverse events included 5.6% with leucopenia.
Adjuvant chemotherapy using gemcitabine showed the potential of contributing to prolonged OS and DFS in stage II resected distal bile duct and ampullary cancers. However, a large cohort will be needed to confirm the overall efficacy in all stages of resected BTC's.
背景/目的：本回顾性研究旨在评估吉西他滨用于切除的远端胆管癌和壶腹癌的辅助化疗效果。
37例接受远端胆管癌和壶腹癌根治性手术的患者被分为两组：A组19例，仅接受手术；B组18例，在2004年至2010年间接受手术加吉西他滨辅助化疗。报告了包括背景、总生存期（OS）、无病生存期（DFS）和不良事件等结果。
A组和B组患者在年龄、性别、肿瘤位置、国际抗癌联盟（UICC）分期、UICC pT因子、UICC pN因子、可治愈性和手术方式等特征方面无差异。除II期外，A组和B组在OS和DFS方面无差异。然而，对于II期患者，A组和B组在OS和DFS的中位生存时间上存在显著差异。3级或4级不良事件包括5.6%的白细胞减少症。
吉西他滨辅助化疗显示出对延长II期切除的远端胆管癌和壶腹癌的OS和DFS有潜在作用。然而，需要大量队列研究来证实其对所有分期切除的胆管癌的总体疗效。
